
|Articles|December 4, 2020
Lurbinectedin: NCCN Guidelines
Advertisement
Newsletter
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
Advertisement
Latest CME
Advertisement
Advertisement
Trending on AJMC
1
Enfortumab Vedotin Plus Pembro Cuts Risk of Disease Progression, Death 60% for Patients With MIBC Who Can’t Have Chemo With Bladder Removal
2
Abemaciclib Plus Endocrine Therapy Improves Overall Survival in High-Risk Early Breast Cancer
3
First-Line Zongertinib Yields Strong Responses in Patients With Advanced HER2-Mutant NSCLC
4
New Biomarkers, Drug Targets Identified for Colorectal Cancer
5